Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an update.
Zhaoke Ophthalmology Ltd. has entered into a distribution agreement with PT Ferron Par Pharmaceuticals to commercialize BRIMOCHOL™ PF, an innovative presbyopia treatment, in Indonesia. This strategic move grants PT Ferron exclusive rights to market and sell the drug, potentially strengthening Zhaoke’s presence in the Southeast Asian market and addressing the unmet need for presbyopia treatments in the region.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Ltd. is a company focused on the ophthalmology industry, specializing in innovative treatments for eye conditions. The company is involved in the development and commercialization of ophthalmic drugs, with a market focus on regions where presbyopia affects a significant portion of the population.
Average Trading Volume: 2,046,997
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.72B
Learn more about 6622 stock on TipRanks’ Stock Analysis page.